Chineo Medical Completes Over RMB 100 Million Pre-B Extension Round to Advance 'Supercharged TIL' Cell Therapy

VCBeat (WeChat ID: vcbeat) has learned that Beijing Chineo Medical Technology Co., Ltd. announced today the completion of a supplementary Pre-B financing round exceeding RMB 100 million, led by Xingjun Capital with follow-on investments from institutions such as Jianxing Fund.

The "Supercharged TIL" immune cell therapy technology, independently developed by Chineo, represents a major upgrade that surpasses its predecessors, building upon the internationally cutting-edge TIL and CAR-T technologies—leveraging patented technologies such as "enhanced receptors" and "expansion factors" to genetically engineer TIL cells, it comprehensively addresses the aforementioned challenges related to solid tumor heterogeneity, the tumor microenvironment, as well as cell expansion processes, manufacturing timelines, and costs.

In addition, the fourth-generation product developed by Chineo—"Super cTIL"—requires only the collection of TIL cells from peripheral blood, overcoming the limitations of traditional TIL therapy that relies on surgically resected tissue samples. This breakthrough has made TIL therapy accessible to virtually all patients, significantly expanding the eligible population.

Dr. Wang Lin, Partner at GaoKe XinJun Capital, stated: “We are delighted to participate in the pioneering innovations in China’s cell therapy sector. As a leading domestic enterprise in TIL technology, Chineo demonstrates strong competitiveness in both technological innovation and clinical translation, having achieved highly encouraging results in both early-stage and ongoing IIT studies. We have every reason to believe that the TIL therapy developed by Chineo will open up a safe, effective, broad-spectrum, and cost-optimized pathway for cancer treatment, enabling as many patients as possible to benefit.”

Neovision Capital is a professional investment institution specializing in venture capital, innovation investment, and mergers & acquisitions in the healthcare and high-tech sectors. Since its establishment in late 2015, it has invested in multiple high-growth enterprises across the biopharmaceutical and high-tech fields. In the biopharmaceutical sector, its representative portfolio companies include Allist Pharmaceuticals (688578), ACROBiosystems (301080), Hualan Shares, Smartee Dental, Rendu Biotechnology, Genway Medical, Yimai Healthcare, Nucletride Medical, and Mapqi Medical, among others.

The Beijing Jianxing Medical and Healthcare Industry Equity Investment Fund (hereinafter referred to as the "Jianxing Medical Fund"), managed by CCB International, is a professional equity investment fund operated with the participation of the Xinhangcheng Fund; this fund was jointly initiated and established by the Beijing Municipal Commission of Economy and Information Technology and the Daxing District Government, with capital contributions from the Beijing High-end and Precision Industry Development Fund and the Daxing Development Guidance Fund. Focusing primarily on high-quality growth-stage projects in fields such as innovative drugs, high-end medical devices, and smart healthcare, the fund leverages the robust biomedical industry foundation in Beijing and Daxing District, CCB International's comprehensive financial service capabilities across the entire industry chain, and the investment team's extensive fund management experience to facilitate the commercialization and implementation of biomedical technological achievements and drive the optimization and upgrading of the industrial structure.

Chineo is a representative enterprise in China for innovative immune cell therapies such as TIL and neoantigen therapies, and has undertaken numerous national and provincial/ministerial-level research projects. The company's "Ultra-Potent TIL" therapy technology is dedicated to conquering solid tumors. Theoretically, it overcomes many limitations of traditional CAR-T, TCR-T, and TIL therapies, offering distinct advantages in safety, efficacy, applicable patient populations, manufacturing cycle, and cost. Clinical trials for the company's "Ultra-Potent TIL" product in the treatment of advanced solid tumors, led by renowned Principal Investigators (PIs) such as Professor Li Jin from Shanghai East Hospital, are currently underway.